NCT00436215View on ClinicalTrials.gov

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 12, 2006

Primary Completion Date

June 26, 2014

Study Completion Date

September 27, 2014

Conditions
Ovarian NeoplasmFallopian Tube CancerPrimary Peritoneal Cancer
Interventions
DRUG

Bevacizumab

bevacizumab 5 mg/kg intravenous (IV) every two weeks

DRUG

BAY 43-9006

BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00436215 - Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | Biotech Hunter | Biotech Hunter